Aug 06, 2020

Efficacy, safety of aspirin for treatment of patients with diabetes, CAD unclear

BOSTON — The benefits of using aspirin, alone or with a platelet inhibitor, for the treatment of patients with diabetes at high-risk for CVD are still unclear, according to presenters at the Cardiometabolic Health Congress. A debate between Ph. Gabriel Steg, MD, professor of cardiology at Paris Diderot University and director of the coronary care unit at Hospital Bichat-Claude Bernard, and

Proceed to the page: http://linkis.com/48xeS

Similar Articles Added Earlier

Similar Articles Added Today

  • The Trust Crisis: How Marketing Can Help

    A recent release from the National Association of Retirement Plan Participants summarizing their 2016 investor behavior study revealed that trust in financial institutions has fallen to an all-time low of just 8 percent. Wow, that means less than one out of every 10 people trusts the industry...

  • The other benefit of changing windows in the very first part of the year is... — My best blog 2376

    pThe other benefit of changing windows in the very first part of the year is that you get to enjoy their benefits throughout the summer s...

  • e5lzwnl957

    Every-thing great always begins with just an idea. Organization is no different. The most successful businessmen have begun using a single thought and spent in it. After the idea clicks, the...

Most Recent healio.com Articles

  • Apixaban superior to warfarin regardless of renal function in patients with AF

    Renal function status had no effect on the superiority of apixaban in efficacy and safety compared with warfarin in patients with atrial fibrillation, according to data published in JAMA Cardiology. In the ARISTOTLE trial, apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) was associated with reduced...

  • Strict glycemic control did not affect survival after CABG

    There was no difference in survival after CABG between patients who underwent a strict glycemic control strategy compared with those who underwent a liberal strategy, according to recent study data. Researchers assessed long-term survival in patients (mean age, 62.7 years; 16% women) randomly...

  • FDA approves drug-coated angioplasty balloon catheter for PAD treatment

    The FDA has approved a percutaneous transluminal angioplasty catheter with a drug-coated balloon for the treatment of peripheral artery disease. The Lutonix 035 drug-coated balloon (Lutonix DCB; Lutonix Inc./C.R. Bard) is the first of its kind, and is intended to reopen superficial femoral and...

Latest Links Processed

0/120